ここから本文です
投稿一覧に戻る

メディシンバ応援の掲示板

#COVID19 $MNOV has submitted to the FDA a Ph 2 trial design that will recruit 40–60 hospitalized COVID-19 patients for its investigation of ibudilast.

Feedback is anticipated within the next 2 weeks, and if approved, topline results would be available in 2 months. (GlobalData)